BRIDGEBIO PHARMA INC - NOTE 2.250% 2/0

CUSIP: 10806XAD4

Q1 2024 13F Holders as of 31 Mar 2024

Type / Class
Debt / NOTE 2.250% 2/0
Market price (% of par)
81.93%
Total 13F principal
$705,552,289
Principal change
-$36,506,420
Total reported market value
$610,874,985
Number of holders
44
Value change
-$20,650,206,952
Number of buys
20
Number of sells
20

Quarterly Holders Quick Answers

What is CUSIP 10806XAD4?
CUSIP 10806XAD4 identifies 10806XAD4 - BRIDGEBIO PHARMA INC - NOTE 2.250% 2/0 in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of BRIDGEBIO PHARMA INC - NOTE 2.250% 2/0 as of Q1 2024

As of 31 Mar 2024, BRIDGEBIO PHARMA INC - NOTE 2.250% 2/0 was held by 44 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $705,552,289 in principal (par value) of the bond. The largest 10 bondholders included Voya Investment Management LLC, Linden Advisors LP, BRAIDWELL LP, D. E. Shaw & Co., Inc., UBS ASSET MANAGEMENT AMERICAS LLC, ADVENT CAPITAL MANAGEMENT /DE/, ARISTEIA CAPITAL, L.L.C., Point72 Asset Management, L.P., Weiss Asset Management LP, and FMR LLC. This page lists 44 institutional bondholders reporting positions for the Q1 2024 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.